Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
E. Wauters
Institutions:
Universitair Ziekenhuis Leuven,
KU Leuven
Observed institutions:
Universitair Ziekenhuis Leuven,
KU Leuven
OpenAlex ID:
A5005203779
LBA78 A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden
2020
·
P. Van Mol
, A. Franken
, et al.
·
Annals of Oncology
·
4
PDF
29P: Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial
2025
·
H. Lena
, L. Paz-Ares
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
P3.18.29 NAPISTAR 1-01: An International Phase I/II Trial of the Novel ADC TUB-040 in Advanced/Metastatic NSCLC Adenocarcinoma
2025
·
A. Starodub
, I. Ruiz Gutierrez
, et al.
·
Journal of Thoracic Oncology
EP.13.16 Safety and Efficacy of Chemoimmunotherapy in Stage IV Small Cell Lung Cancer: A Single-Center Retrospective Analysis
2025
·
A. Peeters
, E. Wauters
, et al.
·
Journal of Thoracic Oncology
21P: Primary analysis of safety, efficacy and immunogenicity of the therapeutic cancer vaccine PDC*lung01 with or without pembrolizumab in NSCLC: A multicenter phase I/II study
2025
·
J.F. Vansteenkiste
, I. Demedts
, et al.
·
Journal of Thoracic Oncology
PDF
100P: Clinical spectrum and outcomes of KRAS mutated advanced stage NSCLC
2025
·
A-S. D’hulster
, E. Wauters
, et al.
·
Journal of Thoracic Oncology
432P: Real-world biomarker testing and treatment patterns in Belgian lung cancer patients: Insights from the AIBED study
2025
·
L. Decoster
, P. Germonpre
, et al.
·
Journal of Thoracic Oncology
119MO Phase I/II trial evaluating the innovative therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with untreated stage IV non-small cell lung cancer
2024
·
J.F. Vansteenkiste
, K. Cuppens
, et al.
·
Immuno-Oncology Technology
PDF
PO-1247 Predictive factors for 90 day mortality in stage III NSCLC patients treated with chemo-radiotherapy
2022
·
M. Lambrecht
, A. Van de Velde
, et al.
·
Radiotherapy and Oncology
Show more works
View as search
Works count:
9
Citation count:
6
H-index:
2
I10-index:
Year
Topic
Type